PSMA-PET visualized primary tumors in 96.7% of patients, showing potential in initial prostate cancer staging. Diagnostic accuracy for pelvic lymph node involvement was 80.9%, with sensitivity and ...

GCN2 supports prostate cancer growth by maintaining amino acid homeostasis, crucial for tumor progression. Inhibition of GCN2 alone activates p53, leading to cell cycle arrest and senescence, ...

“In that randomized trial, we have level 1 evidence showing that patients have less pain and faster return of bowel function when you work at low pressure,” says Ronney Abaza, MD. In this video, ...

“Some of the main implications for urologists is that the risk adapted utilization of BCG, which has been implemented as guidelines, should continue,” says Madison M. Wahlen. In this video, Madison M.

"There are only 2 major organs you can't transplant: the brain and the bladder. So let's take care of the bladder," says Wayne Kuang, MD. In this video, Wayne Kuang, MD, gives an overview of the Man ...

A panelist discusses how Non-muscle Invasive Bladder Cancer (NMIBC) treatment varies by risk stratification (low, intermediate, and high-risk), with BCG immunotherapy being standard for high-risk ...

"What's unique about our conference is the focus is not on just showcasing what our institute has to offer; the real focus is on networking and collaborating with the top institutes in the nation," ...

“The other aspects of the waivers and the things that remain in flux and are not fully fleshed out are going to be things like interstate telehealth,” says Juan J. Andino, MD, MBA. In this video, Juan ...

"The main benefit, I guess, for Aquablation over TURP, is the fact that the sexual side effects are much better when compared to TURP," says Mohamad Baker Berjaoui, MD. Let's say, first, that TURP ...

ABO-101 is a liver-targeting gene editing therapy designed to reduce oxalate production in PH1 by editing the HAO1 gene. The phase 1/2 trial, redePHine, will assess ABO-101's safety, tolerability, and ...

ADI-270 targets CD70-positive cancers and has shown promising preclinical results, including tumor infiltration and resistance to immunosuppressive environments. The trial will evaluate safety, ...

“We really want to understand whether by using this beta emitter, together with the combination of cabazantinib and the nivolumab, we're getting better outcomes than we would expect with the doublet ...